News coverage about Geron Corporation (NASDAQ:GERN) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Geron Corporation earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.685840015159 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Stock to Hold: Geron Corporation (GERN) – Street Observer (press release) (streetobserver.com)
- Geron Corporation (NASDAQ:GERN) Sees Unusual Trading … – Modern Readers (modernreaders.com)
- Span A Spotted Above Span B for Geron Corp (GERN) – MTNV (mtnvnews.com)
- DaVita Inc. (DVA) noted a price change of -1.16% and Geron Corporation (GERN) closes with a move of -0.46% – Stocks Gallery (stocksgallery.com)
- Planet Fitness Inc (PLNT), and Geron Corp (GERN) Seeing Increased Action in Session – FLBC News (flbcnews.com)
Several research analysts recently commented on the stock. BidaskClub downgraded shares of Geron Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Zacks Investment Research downgraded shares of Geron Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, June 14th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Geron Corporation in a research note on Tuesday, July 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $3.88.
Shares of Geron Corporation (GERN) traded down 0.93% on Tuesday, reaching $2.12. 759,295 shares of the company’s stock traded hands. The firm’s market capitalization is $337.53 million. Geron Corporation has a 52 week low of $1.81 and a 52 week high of $3.15. The firm’s 50 day moving average is $2.23 and its 200 day moving average is $2.47.
Geron Corporation (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.38 million. Geron Corporation had a negative net margin of 433.72% and a negative return on equity of 21.30%. The business’s revenue for the quarter was down 19.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) earnings per share. Analysts expect that Geron Corporation will post ($0.18) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Geron Corporation (GERN) Earning Somewhat Positive Media Coverage, Analysis Finds” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2887288/geron-corporation-gern-earning-somewhat-positive-media-coverage-analysis-finds.html.
Geron Corporation Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with MarketBeat.com's FREE daily email newsletter.